+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Development of somatic mutation signatures for risk stratification and prognosis in lung and colorectal adenocarcinomas



Development of somatic mutation signatures for risk stratification and prognosis in lung and colorectal adenocarcinomas



Bmc Medical Genomics 12(Suppl 1): 24



Prognostic signatures are vital to precision medicine. However, development of somatic mutation prognostic signatures for cancers remains a challenge. In this study we developed a novel method for discovering somatic mutation based prognostic signatures. Somatic mutation and clinical data for lung adenocarcinoma (LUAD) and colorectal adenocarcinoma (COAD) from The Cancer Genome Atlas (TCGA) were randomly divided into training (n = 328 for LUAD and 286 for COAD) and validation (n = 167 for LUAD and 141 for COAD) datasets. A novel method of using the log2 ratio of the tumor mutation frequency to the paired normal mutation frequency is computed for each patient and missense mutation. The missense mutation ratios were mean aggregated into gene-level somatic mutation profiles. The somatic mutations were assessed using univariate Cox analysis on the LUAD and COAD training sets separately. Stepwise multivariate Cox analysis resulted in a final gene prognostic signature for LUAD and COAD. Performance was compared to gene prognostic signatures generated using the same pipeline but with different somatic mutation profile representations based on tumor mutation frequency, binary calls, and gene-gene network normalization. Signature high-risk LUAD and COAD cases had worse overall survival compared to the signature low-risk cases in the validation set (log-rank test p-value = 0.0101 for LUAD and 0.0314 for COAD) using mutation tumor frequency ratio (MFR) profiles, while all other methods, including gene-gene network normalization, have statistically insignificant stratification (log-rank test p-value ≥0.05). Most of the genes in the final gene signatures using MFR profiles are cancer-related based on network and literature analysis. We demonstrated the robustness of MFR profiles and its potential to be a powerful prognostic tool in cancer. The results are robust according to validation testing and the selected genes are biologically relevant.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 066446551

Download citation: RISBibTeXText

PMID: 30704450

DOI: 10.1186/s12920-018-0454-7


Related references

Gene expression signatures for predicting prognosis of squamous cell and adenocarcinomas of the lung. Cancer Research 66(15): 7466-7472, 2006

Noninvasive Computed Tomography-based Risk Stratification of Lung Adenocarcinomas in the National Lung Screening Trial. American Journal of Respiratory and Critical Care Medicine 192(6): 737-744, 2015

Somatic mutation of hCDC4 gene is rare in lung adenocarcinomas. Acta Oncologica 45(4): 487-488, 2006

Somatic mutation in synchronous primary adenocarcinomas of the left lung: a case report. International Journal of Clinical and Experimental Pathology 8(7): 8579-8584, 2016

Appreciating the shades of gray: a case for Computer-Aided Nodule Assessment and Risk Yield (CANARY)-based risk stratification of lung adenocarcinomas. Journal of Thoracic Disease 8(10): E1438-E1440, 2016

Risk stratification by somatic mutation burden in Ewing sarcoma. Cancer 2019, 2019

Predictive role of EGFR mutation status on postoperative prognosis in patients with resected lung adenocarcinomas. Zhongguo Fei Ai Za Zhi 16(4): 177-183, 2013

Mutational analysis of EGFR and related signaling pathway genes in lung adenocarcinomas identifies a novel somatic kinase domain mutation in FGFR4. Plos One 2(5): E426, 2007

Multiwalled carbon nanotube-induced gene signatures in the mouse lung: potential predictive value for human lung cancer risk and prognosis. Journal of Toxicology and Environmental Health. Part a 75(18): 1129-1153, 2012

NetNorM: Capturing cancer-relevant information in somatic exome mutation data with gene networks for cancer stratification and prognosis. Plos Computational Biology 13(6): E1005573, 2017

Genome-wide DNA methylation analyses in lung adenocarcinomas: Association with EGFR, KRAS and TP53 mutation status, gene expression and prognosis. Molecular Oncology 10(2): 330-343, 2016

Germline and somatic mutation analyses in the DNA mismatch repair gene MLH3: Evidence for somatic mutation in colorectal cancers. Human Mutation 17(5): 389-396, 2001

Correlation of PD-L1 Expression with Tumor Mutation Burden and Gene Signatures for Prognosis in Early-Stage Squamous Cell Lung Carcinoma. Journal of Thoracic Oncology 2018, 2018

KRAS exon 2 codon 13 mutation is associated with a better prognosis than codon 12 mutation following lung metastasectomy in colorectal cancer. Oncotarget 8(2): 2514-2524, 2016

Common genetic variation in TP53 is associated with lung cancer risk and prognosis in African Americans and somatic mutations in lung tumors. Cancer Epidemiology, Biomarkers and Prevention 16(2): 214-222, 2007